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Objective: Intra-articular (IA) corticosteroids relieve osteoarthritis (OA) pain, but rapid absorption into
systemic circulation may limit efficacy and produce untoward effects. We compared the pharmacoki-
netics (PK) of IA triamcinolone acetonide (TA) delivered as an extended-release, microsphere-based
formulation (FX006) vs a crystalline suspension (TAcs) in knee OA patients.
Method: This Phase 2 open-label study sequentially enrolled 81 patients who received a single IA in-
jection of FX006 (5 mL, 32 mg delivered dose, N ¼ 63) or TAcs (1 mL, 40 mg, N ¼ 18). Synovial fluid (SF)
aspiration was attempted in each patient at baseline and one post-IA-injection visit (FX006: Week 1,
Week 6, Week 12, Week 16 or Week 20; TAcs: Week 6). Blood was collected at baseline and multiple
post-injection times. TA concentrations (validated LC-MS/MS, geometric means (GMs)), PK (non-
compartmental analysis models), and adverse events (AEs) were assessed.
Results: SF TA concentrations following FX006 were quantifiable through Week 12 (pg/mL: 231,328.9 at
Week 1; 3590.0 at Week 6; 290.6 at Week 12); post-TAcs, only two of eight patients had quantifiable SF
TA at Week 6 (7.7 pg/mL). Following FX006, plasma TA gradually increased to peak (836.4 pg/mL) over
24 h and slowly declined to <110 pg/mL over Weeks 12e20; following TAcs, plasma TA peaked at 4 h
(9628.8 pg/mL), decreased to 4991.1 pg/mL at 24 h, and was 149.4 pg/mL at Week 6, the last post-
treatment time point assessed. AEs were similar between groups.
Conclusion: In knee OA patients, microsphere-based TA delivery via a single IA injection prolonged SF
joint residency, diminished peak plasma levels, and thus reduced systemic TA exposure relative to TAcs.
© 2017 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).: V.B. Kraus, Duke University
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Osteoarthritis (OA) is increasingly recognized as a serious con-
dition1. Specifically, people with OA have an increased cause-
specific mortality risk attributable to cardiovascular and gastroin-
testinal disorders2, and those with symptomatic radiographic knee
OA have been shown to have 23% higher risk of dying prematurely
than individuals without OA1. Possible explanations for the excesssearch Society International. This is an open access article under the CC BY-NC-ND
V.B. Kraus et al. / Osteoarthritis and Cartilage 26 (2018) 34e42 35mortality include reduced physical activity; comorbid conditions;
and adverse effects of OA medications, particularly non-steroidal
anti-inflammatory drugs and opioids. There remains a need for
safe therapies that effectively treat the symptoms and functional
consequences of OA.
Inflammation plays a key role in OA pathogenesis. Serial mag-
netic resonance imaging and histopathological analysis of synovial
tissues show synovitis is associatedwithmore severe joint pain and
cartilage loss, and decreased mobility3e11. Thus, synovitis is
increasingly recognized as an important treatment target12e16.
Intra-articular (IA) corticosteroids such as triamcinolone acetonide
crystalline suspension (TAcs) are a mainstay in short-term man-
agement of OA pain17e21. Pain relief associated with IA corticoste-
roids is consistent with their known anti-inflammatory actions,
particularly the regulation of inflammatory transcription factors
and post-transcriptional pathways22e24. The inflamed synovium is
the likely site of IA corticosteroid activity25e28. Synovial tissue
volume not only shrinks in patients with knee OA post-steroid
therapy, but also rebounds when pain relapses29. However, pain
relief associated with IA corticosteroids diminishes in the weeks
following injection18,30e32, most likely due to efflux of drug from
the joint beginning within hours of injection33. This rapid systemic
absorption from the joint not only limits the duration of analgesic
and anti-inflammatory effects of IA corticosteroids, but also can
lead to cardiovascular and metabolic systemic effects34. Drug
development efforts aimed at limiting the rapid efflux and
extending the duration of IA corticosteroid presence may enhance
the magnitude and duration of analgesic effect and mitigate sys-
temic effects.
FX006 is a novel, extended-release, poly (lactic-co-glycolic acid)
(PLGA) microsphere-based TA formulation designed to prolong the
drug's residence time in the synovial tissues and fluid following IA
injection. In vitro experiments show that the crystals of TA from the
TAcs formulation completely dissolve in <2 h; in the same time
period and under the same conditions, <1% of the embedded TA
from the FX006 formulation is released from the PLGA matrix
(Sponsor data on file). Previously, a single, 3-mL, IA injection of
FX006 substantially increased the duration of TA joint residency,
markedly reduced systemic exposure, and demonstrated both
prolonged and increased analgesia relative to TAcs 40 mg in pa-
tients with knee OA35e37. Subsequently, the FX006 diluent recon-
stitution volume was increased from 3 mL to 5 mL to facilitate
microsphere dispersion. The current study was conducted to
characterize the synovial fluid (SF) and plasma TA PK profiles of
FX006 for the 5-mL injection volume and to compare the SF and
plasma TA PK profiles with those of TAcs (1-mL injection volume),
one of the most common IA knee OA therapies.
Patients and methods
Ethical considerations
Study procedures complied with ethical standards of the
responsible committee on human experimentation (institutional
and national) and the Declaration of Helsinki of 1975, as revised in
2000. A central Institutional Review Board was utilized (Schulman
Central IRB, Cincinnati, OH, USA). All patients provided written
informed consent.
Patient eligibility and study design
In this Phase 2 open-label study (clinicaltrials.gov identifier:
NCT02637323), patients with knee OA received a single IA injec-
tion of FX006 (5 mL, delivered dose of 32 mg) or TAcs (1 mL,
40 mg). Patients were sequentially enrolled (10 patients/cohort)into one of six SF collection cohorts: Week 1, 6, 12, 16, or 20 for
FX006 or Week 6 for TAcs. Additional patients were to be assigned
to cohorts as needed, with the intent of collecting SF from 6
patients/cohort.
Study participants were men and women (40 years of age,
body mass index (BMI) 40 kg/m2) with knee OA diagnosed ac-
cording to American College of Rheumatology clinical and radio-
logical criteria38, with symptoms for 6 months prior to screening
and patient-reported index-knee pain for 15 days of the preced-
ing month. Patients with arthroscopic/open surgery of the index
knee (i.e., most painful in patients with bilateral disease) within 12
months of screening or planned/anticipated index-knee surgery
during the study were excluded. Additional exclusion criteria
included uncontrolled diabetes (hemoglobin A1c >7.5%) and
treatment with IA corticosteroids in any joint <6 months; IA hy-
aluronic acid in the index knee <6 months; intravenous or intra-
muscular corticosteroids <3 months; oral corticosteroids <1
month; and/or inhaled, intranasal or topical corticosteroids <2
weeks prior to screening. These same treatments, and any IA
intervention (e.g., non-protocol-specified aspiration) of the index
knee, were prohibited during study participation. Because this
study did not evaluate efficacy, there was no minimum pain-
intensity criterion at entry, and analgesic medications (e.g., non-
steroidal anti-inflammatory drugs and opiates) were allowed.
Study interventions
FX006 powder was reconstituted in diluent containing an
isotonic, sterile, aqueous sodium chloride solution (0.9% weight/
weight [w/w]), carboxymethylcellulose (0.5%w/w)pluspolysorbate-
80 (0.1% w/w) and administered as a 5-mL injection. FX006 dose-
delivery studies determined that this resulted in administration of
32 mg of TA. Commercially available TAcs 40 mg (Kenalog®-40;
Bristol-Myers Squibb Company, Princeton, NJ, USA) was adminis-
tered as a 1-mL injection, allowing comparisons between FX006 and
a current standard of care. Patientswere to avoid strenuous activities
or prolongedweight-bearing activities for 24e48 h post-IA injection
andmaintain a stable level of physical activity throughout the study.
Study assessments
To optimize needle placement and volume of SF collected, in-
dex knee aspirations were performed with ultrasound guidance at
baseline and Weeks 1, 6, 12, 16, or 20 for FX006 cohorts or at
baseline and Week 6 for the TAcs cohort (mean [standard devia-
tion (SD)] actual volume [mL]: 2.03 [3.45]; range: 0e27). Blood
samples were collected at baseline and Hours 1, 2, 4, 6, 8, 10, 12,
and 24 for all patients; Weeks 1, 6, 12, 16 and 20 for FX006-treated
patients; and Week 6 for TAcs-treated patients. Laboratory as-
sessments included non-fasting blood glucose at screening, Day 1
(prior to IA injection), and Week 6 (TAcs cohort) or Weeks 6, 12, 16,
and 20 (FX006 cohorts).
SF and plasma TA concentrations were both measured using
validated liquid chromatography-tandem mass spectrometry (LC-
MS/MS) assays. For SF, frozen samples were thawed at room
temperature, followed by addition of internal standard working/
phosphate-buffered solutions. Following mixing and a liquid-
eliquid extraction (methyl tert-butyl ether and hexanes), the
samples were centrifuged. Using the Janus liquid handling system
(PerkinElmer, Shelton, CT, USA), a portion of each sample's organic
phase was transferred into a 96-well plate. The organic phase was
evaporated, and samples were reconstituted using a methanol/
water mixture prior to injection into a LC-MS/MS (ACE C18,
30 mm  4.6 mm, 3-mm particle size column, water/methanol
mobile phase, ionization in positive mode with a heated
V.B. Kraus et al. / Osteoarthritis and Cartilage 26 (2018) 34e4236nebulizer). Masses monitored for the analyte in SF were 435/415
and 435/397 and for the internal standard were 442/422 and 422/
404. The TA quantification process employed a 2.5 overall dilu-
tion factor.
The lower limits of quantification (LLOQs) differed between the
twomatrices, i.e., 50.0 pg/mL for SF and 10.0 pg/mL for plasma, with
the SF matrix exhibiting less assay sensitivity due to more inter-
ference from the SF components detected at the analyte's retention
time relative to that observed in plasma. The LLOQ of 50 pg/mL
represents 1e2% of the expected maximum concentration (Cmax) in
SF and is judged sufficient to characterize the PK profile of the
analyte in SF.
Safety was assessed throughmonitoring of adverse events (AEs).
Index knees were assessed for tenderness, heat/redness, swelling,
effusion, and Baker's cyst. Clinically significant findings during
screening/baseline were reported as part of the patient's medical
history, while new clinically significant findings or worsened post-
baseline findings were recorded as AEs.Data analysis
The SF and plasma TA concentrations were assessed using non-
compartmental analysis (Phoenix 64®: WinNonlin® [Version 6.4])
models on the SF and Plasma Drug Concentration Populations,
respectively (Fig. 1). Sparse sampling methodology following Day 1
was implemented across the plasma concentration profile to cap-
ture population-based data at the end of the sampling profile. All
plasma concentration values were set to 0 for pre-dose (time 0) and
post-baseline samples thatwere assayed as below the LLOQ (BLOQ);
geometric mean (GM) data are presented. Due to the small number
of patients contributing SF samples at each post-dose time point, we
also employed sparse sampling modeling, with each patient
contributing only a pre-dose sample and one post-dose sample. For
SF samples, pre-dose and post-baseline concentrations BLOQ were
set to 0. To obtain a reasonable estimate of the GM SF values, a scaler
value of 1 was added to each observed concentration value; thus,
values BLOQ for the computation of GM appear in the descriptive SF
summaries as a value of 1. TA concentration datawere presented by
time point pooled across FX006 cohorts and separately for the TAcs
cohort.
The PK non-compartmental analysis models were completed
using Phoenix® 64 WinNonlin® (Version 6.4) using the PK Popu-
lation (Fig. 1), and graphical displays of PK analyses and concen-
tration informationwere completed with Sigma Plot (Version 13.0).
PK parameters derived from plasma TA concentrations were either
observed or estimated by WinNonlin® (Version 6.4). A linear
trapezoidal rule was applied to compute observed area under the
plasma concentrationetime curve (AUC). Partial AUC parameters
were computed for the intervals AUC0e24 h and AUC0e6 weeks. Pa-
tients contributing samples at Week 1, 12, 16, or 20 provided in-
formation to compute partial AUCs for these intervals. When
sufficient informationwas available to estimate a terminal rate (lz)
constant, the extrapolated parameters (half-life [t½], AUC0e∞,
clearance, mean residence time [MRT0e∞]) were estimated.
AEs were coded using the Medical Dictionary for Regulatory Ac-
tivities (Version18.0). Concomitantmedicationswere codedusing the
World Health Organization Drug Dictionary (March 2014 edition).
No formal sample size computations were completed for this
descriptive study. A minimum of 10 patients/cohort was planned to
provide 6 patients/cohort providing SF TA concentration data for
estimation of GM values to within approximately 3-fold with 95%
confidence. The sample size of 10 patients/cohort also was
considered sufficient to characterize the FX006 PK profile using a
5-mL injection volume.Results
Patient disposition
The study was conducted from 11/30/2015 through 9/8/2016 at
four United States study centers. Eighty-one enrolled patients
received a single IA injection of FX006 (N ¼ 63) or TAcs (N ¼ 18) on
Day 1. Patients sequentially enrolled into FX006 SF collection co-
horts included: 13 for the Week 1; 20 for the Week 6; and 10 each
for the Weeks 12, 16, and 20 cohorts (Table I). Three patients dis-
continued the study early (two FX006 lost to follow-up (LTFU), one
TAcs protocol non-compliant).
Sixty of 63 (95.2%) FX006 and 18/18 (100%) TAcs patients were
included in the Plasma Drug Concentration and PK Populations.
Twenty-nine of 63 (46.0%) FX006 and eight of 18 (44.4%) TAcs pa-
tients were included in the SF Drug Concentration Population. Not
all cohorts achieved6 patients providing SF samples at later visits,
primarily due to <0.1 mL of SF being aspirated at the final sampling
time point, yielding 2e9 patients/cohort and 37/81 (45.7%) patients
across all cohorts providing SF samples. Details of the Safety,
Plasma Drug Concentration, SF Drug Concentration, and PK pop-
ulations are provided in Fig. 1.
Baseline characteristics
Among patients treated across study cohorts (Safety Popula-
tion), the 36 (44.4%) men and 45 (55.6%) women had a mean age of
60 years, mean BMI ranging from 30 to 32 kg/m2 across cohorts,
mean time since primary OA diagnosis of almost 8 years, and a
mean of 29 days of index-knee pain within the month preceding
screening. As expected, based on lack of randomization and rela-
tively small cohort sample sizes, baseline characteristics varied
across cohorts (Table I).
FX006 SF and plasma TA concentrations
Following a single IA injection of FX006, the GM SF TA Cmax of
231,321.3 pg/mL was reached at a median time to maximum con-
centration (tmax) of 168.0 h (i.e., Week 1). Thereafter, SF TA con-
centrations declined, with GMs of 3590.0 pg/mL at Week 6 and
290.6 pg/mL at Week 12. After Week 12, TA was BLOQ in the small
number of SF samples obtained (Fig. 2).
FX006-TA demonstrated some systemic absorption, with a
plateau in plasma TA concentrations through Hour 24 followed by
slowelimination from the systemic circulation (Fig. 3). The GM Cmax
(966.7 pg/mL) was reached at a median tmax of 7.0 h. The median t½
was 347.0 h, GM MRT was 453.7 h, and GM clearance was slow
(0.0001mL/h/kg). The GM last measurable concentration (106.4 pg/
mL) was observed at a median time to last measurable concentra-
tion (tlast) of 1008.0 h (approximately Week 6) (Table II).
TAcs SF and plasma TA concentrations
Following a single IA injection of TAcs, TA SF concentrations
were BLOQ atWeek 6 (Fig. 2). Of the eight patients who contributed
samples at Week 6, only two had measurable SF TA concentrations
at this time point, yielding a GM SF TA concentration of 7.7 pg/mL,
notably lower than that seenwith FX006 atWeek 6 (3590.0 pg/mL).
Systemic TA absorption was relatively rapid post-TAcs injection,
with GM plasma TA concentrations determined for each sampling
time point peaking at 4 h (9628.8 pg/mL) and declining to
4991.1 pg/mL at Hour 24 post-injection (Fig. 2). The observed GM
Cmax of 11,064.7 pg/mL was reached at a median tmax of 6 h. The
median t½ (72.5 h) was shorter than that seenwith FX006. GMMRT
Fig. 1. Patient disposition. D/C e discontinuation, LTFU e lost to follow-up.
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mL, which was 6 higher than that observed with FX006 (Table II).
Safety
AEs were reported for 11.1% (7/63) of FX006-and 11.1% (2/18) of
TAcs-treated patients. The only AEs reported by >1 patient were
hypertension in two FX006-treated patients (both with a history of
hypertension) and flushing in twoTAcs-treated patients (considered
to be related to the injection procedure in both patients). The vast
majority of AEswere Grade-1 or 2 and assessed by the investigator to
be unrelated to study drug. One Grade-4 pulmonary embolism
occurred in an FX006-treated patient with a history of pulmonaryembolism (serious AE considered unrelated to study drug, injection
procedure, or index knee). The AEs considered related to study drug
were a Grade-1 arthralgia and a Grade-2 patellofemoral pain syn-
drome in FX006-treated patients and the Grade-1 flushing noted
above in two TAcs-treated patients. The incidence of index-knee-
related AEs in the patients treated with FX006 was 3.2% (2/63). No
patient died or discontinued due to an AE.
Discussion
Results of this Phase 2 open-label study indicate that
microsphere-based extended-release delivery of TA via a single
5-mL IA injection of FX006 prolonged TA IA residency time,
Table I
Baseline demographic, patient, and disease characteristics by cohorts (safety population)
Parameter FX006 cohorts All FX006 (N ¼ 63) TAcs cohort
Week 1 (N ¼ 13) Week 6 (N ¼ 20) Week 12 (N ¼ 10) Week 16 (N ¼ 10) Week 20 (N ¼ 10) Week 6 (N ¼ 18)
Male e n (%) 7 (53.8) 6 (30.0) 5 (50.0) 6 (60.0) 7 (70.0) 31 (49.2) 5 (27.8)
Age (years) 55.5 (8.61) 58.8 (7.02) 57.2 (6.61) 67.3 (6.04) 63.0 (8.08) 59.9 (8.16) 61.9 (7.68)
BMI (kg/m2) 30.7 (4.66) 30.3 (4.16) 31.9 (6.17) 29.4 (4.76) 32.3 (4.38) 30.8 (4.69) 32.0 (4.32)
Years since primary
diagnosis
3.8 (2.68) 8.3 (7.66) 8.1 (5.97) 14.8 (5.31) 4.7 (2.67) 7.8 (6.53) 7.92 (6.46)
KellgreneLawrence grade e n (%)
1 1 (7.7) 3 (15.0) 1 (10.0) 0 0 5 (7.9) 4 (22.2)
2 7 (53.8) 10 (50.0) 3 (30.0) 7 (70.0) 2 (20.0) 29 (46.0) 7 (38.9)
3 5 (38.5) 7 (35.0) 4 (40.0) 3 (30.0) 6 (60.0) 25 (39.7) 5 (27.8)
4 0 0 1 (10.0) 0 2 (20.0) 3 (4.8) 2 (11.1)
Unknown 0 0 1 (10.0) 0 0 1 (1.6) 0
Days with index-knee pain* 28.5 (3.26) 27.9 (3.02) 29.8 (1.40) 28.8 (3.79) 28.7 (4.11) 28.6 (3.18) 29.1 (3.02)
Data presented are mean (SD) unless noted otherwise.
* Within the month prior to screening.
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systemic TA exposure relative to a single IA injection of a standard
crystalline suspension of TA. Over the first week following IA FX006
injection, TA concentrations in the systemic circulation plateaued at
low levels relative to values produced by TAcs, suggesting that TA
remains in the SF and synovial tissues following injection, with
slow absorption into systemic circulation. Prolonged joint resi-
dency is further supported by assessments of local TA concentra-
tions in SF showing variable but quantifiable levels out to Week 12
post-injection, whereas those post-TAcs were either very low (two
patients) or not quantifiable (six patients) at Week 6.
Synovial concentrations of TA e clinical implications
The differences in SF TA concentrations observed in this
studydGMs of 3590.0 and 290.6 pg/mL at Week 6 and Week 12,
respectively, for FX006 and 7.7 pg/mL at Week 6 for TAcsdlikely
constitute the basis for pharmacologic differentiation and provide a
rational hypothesis for between-treatment efficacy differences
observed in Phase 2/3 trials37,39,47. For example, exploratoryFig. 2. SF TA concentrations (log-linear scale) over time following a single IA injection of
was added to each observed concentration value. CI e confidence interval.analyses from a Phase 3, multicenter, double-blind, 24-week study
showed that the same dose of FX006 demonstrated statistical im-
provements in pain, stiffness, and physical function, as assessed by
the Western Ontario & McMaster Universities Osteoarthritis Index
(WOMAC), at Weeks 4, 8, and 12 vs TAcs in patients with knee OA39.
These effects are clinically important; post-hoc analyses demon-
strated that the improvements in all WOMAC subscale scores
afforded by FX006 exceeded the minimum clinically important
improvement (MCII) thresholds utilized by the American Academy
of Orthopedic Surgeons (AAOS)39e42. Specifically, FX006 effects
achieved the AAOS definition of ‘clinically significant’ at Weeks 4
and 8 and ‘possibly clinically significant’ at Week 12 for all WOMAC
subscale scores39,40. Conversely, TAcs never achieved the AAOS
definition of ‘clinically significant’ at any time point for any
WOMAC subscale39,40. These results represent the first time an
injectable OA therapy has surpassed the AAOS-defined threshold
for ‘clinical significance,’ and are likely attributable to sustained TA
occupancy of the corticosteroid receptor afforded by the prolonged
IA residency of TA associated with FX006 relative to TAcs reported
herein. Similarly, animal studies have shown the anti-inflammatoryFX006 or TAcs. To obtain a reasonable estimate of the GM SF values, a scaler value of 1
Fig. 3. Blood plasma TA concentrations (log-linear scale) over time following a single IA injection of FX006 or TAcs.
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delivery or targeting to inflamed synovial tissues as assessed
histologically.43,44
Systemic concentrations of TA e clinical implications
The plasma TA concentration profile associated with FX006 in
this studyda GM of 759.5 pg/mL at 4 h post-injection that pla-
teaued over the first 24 h, followed by a slow decline to ~100 pg/mL
through Week 20dindicates TA remains in the SF and tissues
following IA injection, with corresponding slow elimination into
systemic circulation (Fig. 3). These data are consistent with the
results from two prior studies in patients with knee OA that
included plasma PK sampling after a single injection of the same
dose of FX006; plasma TA concentration curves over time were
similar across studies36,37. Conversely, systemic TA absorption was
rapid following IA injection of TAcs: plasma TA concentrations
reached a GM Cmax of 11,064.7 pg/mL at a median tmax of 6 h, and
declined to 4991.1 pg/mL by 24 h. A similar plasma TA concentra-
tion profile following TAcs also was reported in a previous study inTable II
Plasma PK parameters for pooled FX006 and TAcs cohorts (plasma drug concentration p
PK Parameter FX006 pooled cohorts (5-mL
volume)
Cmax (pg/mL), GM N ¼ 60
AUC0e24 h (h * pg/mL), GM N ¼ 60
AUC0e6 weeks (h * pg/mL), GM N ¼ 60
AUC0e12 weeks (h * pg/mL), GM N ¼ 14
AUC0et (h * pg/mL), GM N ¼ 60
AUC0einf (Observed) (h * pg/mL), GM N ¼ 33
tmax (h), median N ¼ 60
t1/2 (h), median N ¼ 33
tlast (h), median N ¼ 60
Clast (pg/mL), GM N ¼ 60
V(ss) (Observed) (mL/kg) N ¼ 33
CL ([mL/h]/kg), GM N ¼ 33
MRT (h), GM N ¼ 33
AUC (0einf ¼ time 0 extrapolated to infinity; 0et ¼ time 0 to the last quantifiable concen
CL e clearance, Clast e last measurable concentration, V(ss) e steady state volume of dist
* Measurements for TAcs extended through Week 6; those for FX006, depending on th
with the time point at which synovial TA concentrations remained quantifiable.patients with knee OA, in which levels peaked at approximately
13,000 pg/mL on Day 1 and decreased in a log-linear manner to a
value of approximately 100 pg/mL on Day 1837. The difference in
systemic TA profiles resulting from IA FX006 compared with IA
TAcs is underscored by the results from a post-hoc analysis used to
demonstrate bioequivalence45, which confirmed significantly
lower systemic TA exposure following FX006 relative to TAcs
(Online Supplement, Table S1).
While the total systemic exposure to TA from FX006 is sub-
stantially lower than that of TAcs, the duration of measureable
levels of TA associated with FX006 is longer due to the extended-
release mechanism of the PLGA microsphere. In a prior study,
persistent low levels of systemic TA resulting from the same dose of
FX006 were examined to determine whether or not they affected
the function of the hypothalamic-pituitary-adrenal axis as
measured by serum cortisol in patients with knee OA35. Through
Week 6 post-injection, the cumulative cortisol suppression asso-
ciated with FX006 was similar to that associated with TAcs35. As
such, it is unlikely that IA administration of FX006 will compromise
cortisol production or responses to stress throughout its duration ofopulation)
injection TAcs cohort (1-mL injection volume)
966.7 N ¼ 18 11,064.7
17,908.8 N ¼ 18 173,690.8
508,939.6 N ¼ 17 3,082,834.8
512,607.9* Not assessed* Not assessed*
440,718.6* N ¼ 18 594,276.8*
543,115.0 N ¼ 14 1,248,903.3
7.0 N ¼ 18 6.0
347.0 N ¼ 14 72.5
1008.0 N ¼ 18 24.0
106.4 N ¼ 18 1508.6
0.0497 N ¼ 14 0.0029
0.00012 N ¼ 14 0.0000
453.7 N ¼ 14 60.9
tration; 0e24 h, 6 weeks, 12 weeks¼ time 0e24 h, 6 weeks, 12 weeks, respectively),
ribution.
e cohort, extended to Week 6, Week 12, Week 16 or Week 20. AUC0e12 weeks aligns
V.B. Kraus et al. / Osteoarthritis and Cartilage 26 (2018) 34e4240exposure in patients with intact hypothalamic-pituitary-adrenal
axis function.
Differences in systemic TA absorption following FX006 or TAcs IA
injection may have clinical significance. Results from a recent study
of patients with knee OA and type-2 diabetes mellitus assessing the
effects of FX006 and TAcs on blood glucose over 72 h post-injection
showed that FX006 was associated with a statistically significant
(P < 0.05, 2-sided) and clinically relevant reduction in the rise of
blood glucose46. As such, the overall reduced systemic TA exposure
associated with FX006, particularly the low peak concentrations,
suggests that FX006 has the potential to confer an improved safety
profile relative to TAcs; additional studies are needed.
Safety data e clinical implications
Safety data from the 63 FX006-treated and 18 TAcs-treated
patients identified no new or unexpected safety concerns for
either agent. These findings are consistent with those observed in
larger Phase 2/3 clinical trials of FX006, in which a single IA FX006
injection demonstrated systemic and local safety profiles generally
similar to placebo and TAcs, and no post-injection flares were
observed.37,39,47
Despite prolonged TA joint residence associated with micro-
sphere delivery, index-knee related AEs were limited to two FX006-
treated patients (Grade-1 arthralgia, Grade-2 patellofemoral pain
syndrome). This lack of adverse local effect is not unexpected given
that the FX006 PLGAmatrix degrades to oligomeric poly-acid units,
then to lactic and glycolic acids48, followed by elimination as carbon
dioxide and water.
Study limitations
Results are limited by small sample sizes and acquisition of
fewer-than-planned SF samples. Patients were not randomized, but
were sequentially enrolled starting with FX006 and followed by
TAcs treatment groups. Nonetheless, findings are generally
consistent with SF and plasma PK evaluations conducted for the
earlier FX006 3-mL formulation, which also showed that FX006
substantially reduced systemic exposure to, and prolonged IA
residence of, TA relative to TAcs35e37. Specifically, in a previous
assessment of SF TA concentrations, variable but quantifiable TA
levels were observed through 16 weeks post-injection37. Addi-
tionally, FX006 (3-mL formulation) produced substantially lower
peak plasma TA concentrations than TAcs when given at matched
doses in a larger (N ¼ 228), double-blind, randomized, multicenter,
Phase 2 trial in knee OA.37
Conclusions
These SF and plasma PK observations are consistent with slow
release of TA into SF and tissues and blunted absorption into sys-
temic circulation following a single IA injection of FX006 micro-
spheres, yielding prolonged IA residency of TA relative to TAcs in
patients with knee OA.
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